Farletuzumab clinical trials
Also written MORAb-003.
How each study uses farletuzumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
9 studies that test it; most in 2010 (2)
| Year | Studies |
|---|---|
| 2005 | 1 |
| 2006 | 1 |
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 2 |
| 2011 | 2 |
| 2015 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 9 · Other 0
Studies
Open first, then newest update. How each study uses farletuzumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 9
- Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First RelapseTerminatedPhase 3MorphotekNCT00849667Written as Farletuzumab
- An Open Label Extension Study of the Efficacy of MORAb-003TerminatedPhase 2MorphotekNCT01018563Written as MORAb-003
- A Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination With Carboplatin Plus Paclitaxel or Carboplatin Plus Pegylated Liposomal Doxorubicin (PLD) in Participants With Low CA125 Platinum-sensitive Ovarian CancerCompletedPhase 2Eisai Inc.NCT02289950Written as Farletuzumab
- A Safety and Efficacy Study of Farletuzumab in Participants With Adenocarcinoma of the LungCompletedPhase 2MorphotekNCT01218516Written as Farletuzumab
- A Study of MORAb-003 in Patients With Solid TumorCompletedPhase 1Eisai Co., Ltd.NCT01049061Written as MORAb-003
- An Efficacy and Safety Study of MORAb-003 in Platinum-Resistant or Refractory Relapsed Ovarian CancerTerminatedPhase 2MorphotekNCT00738699Written as MORAb-003 (farletuzumab)
- Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based ChemotherapyCompletedPhase 2MorphotekNCT00318370Written as Farletuzumab
- Safety, Tolerability and Pharmacokinetics of MORAb-003 in Subjects With Advanced Ovarian CancerCompletedPhase 1MorphotekNCT00428766Written as MORAb-003
- Exploratory Study of Farletuzumab to Treat Resectable, Non-functioning Pituitary AdenomasWithdrawnPhase 2MorphotekNCT01203618Written as Farletuzumab
Codes
What other systems call farletuzumab · ClinicalTrials.gg INT005242
- MeSH (NLM) C527484farletuzumabConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 2O09BG0OWAFARLETUZUMABConfirmed FDA, NLM, Wikidata
- Wikidata Q3739631farletuzumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C61503FarletuzumabOne source FDA
- DrugBank DB05595One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C527484 | farletuzumab | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 2O09BG0OWA | FARLETUZUMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q3739631 | farletuzumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C61503 | Farletuzumab | One source FDA |
| DrugBank | DB05595 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.